👉OBIO is TODAY’S #1 ALERT*

Hey Team, Jeff Bishop here,

I hope you’re strapped in, because we’re in for a very interesting week in the markets.

Over the weekend, President Trump called for a one-year cap on credit card interest rates at 10%, which has led bank stocks, in particular, to take a hit.

We also learned of a criminal investigation into Fed Chair Powell for his congressional testimony about the Fed’s multi-billion-dollar headquarters renovation.

Naturally, this has sparked investor fears about Fed independence, and stock futures took a hit this morning.

💥My focus right now is on stocks that have enough momentum to power through the headwinds, and at the top of my watchlist is Orchestra BioMed Holdings, Inc. (OBIO)*.

OBIO is a biomedical innovation company that’s developing medical technologies for cardiovascular disease.

It’s still in the pre-commercial stage, so its cash runway is crucial for investors…

In Q3/Q4 2025, the company raised a whopping $147 million in new capital, including strategic investments of $31.6 million by Medtronic, $40 million by Ligand, and $30 million by Terumo.

OBIO says this new capital extended its runway through key milestones into Q4 2027.

That’s great news for investors, understandably concerned about dilution in a pre-commercial-stage company, and the stock has rallied accordingly…

From its September 24 low at $2.20, the stock has ripped 118% to close at $4.80 on Friday.

But as I point out below, the stock has an average price target of $14.25 — 198% over Friday’s closing price — based on 4 analysts’ price targets from the last 3 months.

And that was before the big news out just this morning that OBIO expects to receive up to $21 million in cash proceeds thanks to the Haemonetics Corporation acquiring Vivasure, a strategic holding of OBIO prior to the transaction.

There was already a lot of optimism around this ticker, so it’s no surprise to see the stock surging in the pre-market on the news. I’m watching it closely for a big gap up today.

👉  OBIO is TODAY’S #1 ALERT* 👈

Here are five things about the company that stand out to me:

1. It’s reinventing how we treat high blood pressure 🔥 

The company notes that hypertension is the “leading global risk factor for death, affecting 1.2B patients.” OBIO is developing Atrioventricular Interval Modulation (AVIM) Therapy as a firmware enhancement to pacemakers that actively lowers blood pressure instead of relying on drugs. 

The company believes there are about 4.5 million “highly addressable patients,” adding up to a $17 billion annual global opportunity.

2. The FDA awarded AVIM Therapy a Breakthrough Device Designation 🧠

Last April, the FDA granted a Breakthrough Device Designation for the company’s AVIM Therapy.

That designation “is designed to expedite the development and provide priority review of innovative medical technologies that have the potential to significantly improve outcomes for patients with serious or life-threatening conditions.” [emphasis added]

This could mean a faster path to approval if results keep impressing.

3. The company has locked in serious strategic partnerships 🤝

OBIO has partnered with industry giants..

The BACKBEAT global pivotal study into AVIM therapy is being conducted in collaboration with $125-billion-market-cap Medtronic, one of the largest medical device companies in the world.

In total, Medtronic has a $61.6 million equity investment in OBIO plus a $20 million strategic capital commitment.

On its other lead program, Virtue SAB, the company has teamed up with $22-billion-market-cap Terumo, which has provided OBIO with $65 million in payments and investments as part of a ROFR (Right of First Refusal) agreement with respect to the global coronary market.

4. The company has raised serious money to push clinical programs forward 💰

As mentioned, in Q3/Q4 2025 alone, OBIO secured over $147M in strategic capital and commitments to advance their pivotal trials.

And the structure of that capital — public offerings plus strategic investments tied to future revenue — means there’s aligned skin in the game between OBIO and partners like Medtronic, Terumo, and Ligand.

This kind of financial runway isn’t typical for a microcap medtech, so it’s actually funded to hit the milestones that could drive valuation.

5. It’s balancing big market opportunities and retail investor interest 📊

The stock itself has caught attention — trading with a market cap around $270M and significant retail ownership, while institutions also hold meaningful positions.

That’s interesting because it means OBIO has:

• Smart capital backing it
• Retail traders watching the story
• And biotech titans who see the long-term promise

Final Thoughts

OBIO has attracted considerable, recent analyst interest. One analyst gave it a “hold” rating back in August, but all the more recent ratings set price targets with triple-digit upside:

As you do your own research on OBIO, be sure to check out the company website and this investor presentation released just this month.

And of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*ISSUER-PAID DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Orchestra BioMed Holdings (via Stock AI News) for a one day marketing program starting on January 12, 2026.

It might seem obvious, but while our client claims not to own any shares in Orchestra BioMed Holdings, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Orchestra BioMed Holdings might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.